Philip Morris to sell Vectura as Dutch group prepares IQOS criminal complaint

Philip Morris International agreed to sell Vectura to Molex Asia Holdings for a fraction of the GBP 1.1 billion it paid three years ago, while a Dutch anti-smoking foundation prepares criminal charges over IQOS marketing.

The Vectura sale removes a drug-delivery business PMI bought three years ago

PMI is offloading Vectura, an inhaled-medicine and drug-delivery specialist, to Molex Asia Holdings, according to a Pharmaphorum report cited in coverage of the week ending 7 November 2026. The price is a fraction of the GBP 1.1 billion PMI paid for the business.

The article gives no final consideration, completion date or deferred-payment terms, so the transaction’s effect on PMI’s balance sheet is not yet quantifiable. The disposal narrows the company’s operations outside its core nicotine portfolio.

A Dutch foundation says it will file criminal charges by mid-November

The Foundation for Youth Smoking Prevention plans to lodge criminal charges against Philip Morris with Dutch prosecutors, NL Times reported on 2 November 2026. The group alleges PMI misled consumers about the health risks of its heated-tobacco system and breached restrictions on nicotine advertising.

The filing is expected by mid-November. No court has established the allegations.

The same reporting says the Dutch National Institute for Public Health and the Environment (RIVM) considers heated tobacco harmful and not a safe alternative to smoking.

Two events in one week touch capital and legal exposure

The share price quoted does not settle the financial questions

The real-time Lang & Schwarz quote for Philip Morris stock stood at EUR 177.58 at 11:47 CET on 7 November 2026, according to the coverage. That is the ISIN US7181721090 line.

This figure records the market at a point in time and does not measure the Vectura proceeds or any liability from the Dutch process.

Analysis: what supply-chain companies should watch

For manufacturers and distributors working with PMI’s heated-tobacco lines, the Dutch action matters more than the divestment, because it targets marketing conduct rather than hardware. Compliance teams that supply or co-market IQOS devices in the EU should expect closer scrutiny of consumer-facing risk statements and advertising collateral while the complaint is pending. The Vectura exit signals a tighter focus on nicotine products, which suppliers can read as a preference for core-category partnerships over diversification. These are VapeBrief’s inferences from the reported facts, not statements by PMI.

Investors get details only when the sale terms and the filing are confirmed

PMI has not disclosed the Vectura consideration, timetable or deferred structure in the material available, and the Dutch complaint had not been filed as of the reporting. The next dated step is the expected mid-November filing with Dutch prosecutors. The completion terms of the Vectura sale are the other open item that will determine how the transaction reads financially.

Questions readers ask

What is Philip Morris International selling Vectura for?

The available reporting does not state the consideration. It says only that Molex Asia Holdings is paying a fraction of the GBP 1.1 billion PMI paid for Vectura three years earlier, and that final terms and any deferred payments are undisclosed.

Has the Dutch criminal complaint against Philip Morris been filed?

No. The Foundation for Youth Smoking Prevention announced plans to file criminal charges with Dutch prosecutors, with the filing expected by mid-November 2026. The allegations have not been established by a court.